3 Reasons Hospira, Inc. Stock Could Fall

Let’s take a look at three reasons Hospira’s stock could fall.

Aug 22, 2014 at 12:35PM

The market is very bullish on Hospira (NYSE:HSP), which has rallied impressively over the past 12 months.

HSP Chart

Source: YCharts.

The maker of specialty injectable pharmaceuticals and medical devices has certainly been on fire -- revenue rose 11% year-over-year last quarter as adjusted earnings per share climbed 31%. Hospira topped off those strong results with higher top and bottom line guidance for the rest of the year. The company also announced that the FDA had cleared its troubled Rocky Mount plant in North Carolina, which has weighed on its bottom line for three years. It is also reportedly interested in acquiring Danone's medical nutrition unit, which could cut its corporate tax rate by moving to France and diversify its portfolio.

While that's all great news for the bulls, investors should also look at three of the top contrarian arguments as well. But before we do so, investors should remember that while these points highlight Hospira's fundamental weaknesses, they do not guarantee that the stock will fall.

1. Generic competition for Precedex
One of Hospira's greatest strengths is its biosimilars portfolio, which contains generic versions of drugs like Remicade, Procrit/Eprex, and Neupogen. That's why it's ironic that one of Hospira's biggest drugs, Precedex, is being copied by its rivals.

Precedex, a liquid sedative for intensive care units, accounted for 11% of Hospira's 2013 revenue of $4 billion.

Novartis' (NYSE: NVS) Sandoz reached a deal with Hospira, which will allow it to launch generic Precedex in December. Sandoz isn't the only one interested in launching generic Precedex -- Akorn (NASDAQ: AKRX) informed Hospira in June 2012 that it also intended to sell generic Precedex. Hospira sued Akorn in April 2014, presumably to delay the company and other rivals besides Sandoz from launching generic Precedex.

Therefore, investors should note that although Hospira raised its top and bottom line guidance for the full year, its growth could eventually suffer due to the loss of exclusivity for Precedex, despite the company's efforts to delay the inevitable.

2. Overseas plants are still in trouble
While it was encouraging that Hospira's Rocky Mount troubles finally ended, the company still has to contend with troubles in Costa Rica and India.

The embargo of pumps made at Hospira's Costa Rica plant, issued by federal regulators last February, has been a big damper on the company's medical device business. After the FDA ban, Hospira signed a deal with Q Core Medical to launch the Sapphire system, a new infusion pump to replace the older GemStar line which was banned by the FDA due to the problems in Costa Rica. That move has propped up Hospira's medication management business, but the segment still posted nearly flat growth last quarter.

Meanwhile, Hospira's plant in Irungattukottai, India was hit by an FDA warning letter last May over sterilization practices, followed by a follow-up inspection which resulted in nearly two dozen observations. To make matters worse, Hospira's new plant in India at Vizag -- which Hospira has already spent over $200 million on -- is being heavily scrutinized by the FDA.

3. What goes up must come down
While Hospira doesn't have any identical competitors, Baxter International's (NYSE: BAX) Medical Products division (which sells pumps and injectables) is similar to Hospira's core business, while Teva Pharmaceutical (NYSE: TEVA) competes against Hospira with a similar mix of generic and specialty pharmaceuticals. Hospira's stock trades at a considerable premium to both.



Baxter International



Market cap

$9.4 billion

$40.7 billion

$44.4 billion


Trailing P/E (12 mo.)





Forward P/E





Price-to-sales (12 mo.)





Source: Yahoo Finance, Aug. 19.

It may be unfair to compare Hospira to Baxter and Teva, which are both much larger and have less growth potential, but investors should note that Hospira trades with a trailing P/E more similar to high-flying biotechs than a maker of injectable drugs and medical pumps.

This means that if the market gets dicey, Hospira could quickly lose its momentum and drop a lot faster than its larger rivals.

A Foolish final word
In conclusion, investors should be aware that Hospira's robust top and bottom line growth could easily be weighed down by inevitable declines in Precedex sales and additional expenses related to plants in Costa Rica and India. Hospira is also rising with a lot of momentum, which means that it might need to take a breather to reconcile its stock price with its underlying valuations.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Baxter International and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information